Transmenu powered by JoomlArt.com - Mambo Joomla Professional Templates Club

8 February 2010
Silence Therapeutics Receives Notice of Allowance for RNAi Patent Covering Novel Cancer Target

5 February 2010
Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference

5 January 2010
Silence and Intradigm complete merger to form a leading company in the field of RNAi

4 January 2010
Shareholders pass all resolutions at EGM

16 December 2009
Silence Therapeutics to merge with Intradigm Corp to create leading RNAi therapeutics company

16 December 2009
Admission Document – Circular to Shareholders in full
download Admission Document

14 December 2009
Shareholders pass all resolutions at AGM

15 October 2009
Silence Therapeutics’ core patent upheld

30 September 2009
Silence announces Interim Results for the six months ended 30 June 2009

29 September 2009
Silence announces temporary suspension of shares pending outcome of M&A talks

17 September 2009
Silence will release its interim results for the 6 months to 30 June 2009 on 30 September 2009

27 August 2009
Silence Therapeutics signs siRNA delivery collaboration with Dainippon Sumitomo Pharma

23 June 2009
Silence announces dosing of first patient in Atu027 cancer trial

3 June 2009
Silence receives approval to commence Phase I clinical trial with Atu027

21 January 2009
Successful oppostion to 2^nd EP on Keutzer-Limmer

9 January 2009
EPO grants Silence Therapeutics’ Patent